ASPET

JUNE 27, 2024

Estrogen receptor (ER)-negative breast cancers are known to be aggressive and unresponsive to anti-estrogen therapy, and triple negative breast cancers are associated with poor prognosis and metastasis. Thus, new targeted therapies are needed.

Therapies 100

Therapies Protein Expression 100

Alta Sciences

OCTOBER 29, 2024

PBSS - Boston—Preclinical Development and IND Filing for new modalities, ADCs, SiRNA/ASO, Gene and Cell Therapies iianiro Tue, 10/29/2024 - 18:14 Image cambridge-massachusetts.png Synopsis Boston, MA URL [link] Event End Date Wed, 11/06/2024 - 12:00 Event Start Date Wed, 11/06/2024 - 12:00 Weight 1

Therapies 40

Therapies 40

ASPET

JUNE 30, 2023

Myeloproliferative Neoplasms (MPNs) are hematological malignancies that result from acquired driver mutations in hematopoietic stem cells (HSCs), causing overproduction of blood cells and an increased risk of thrombo-hemorrhagic events. The most common MPN driver mutation affects the JAK2 gene ( JAK2 V617F ).

Therapies 100

Therapies Treatment Drugs 100

Vial

DECEMBER 8, 2023

With technological innovation and scientific research propelling the development of new therapies, anticipation for the future is high. As we look forward to 2024, several groundbreaking therapies are poised to radically change the landscape of ophthalmology, providing hope and improved treatment options for patients with ocular conditions.

Therapies 52

Therapies Clinical Trials Trials Treatment 52

Alta Sciences

JUNE 11, 2024

My Attendance at the 2024 Boston Society Cell and Gene Therapy Conference pmjackson Tue, 06/11/2024 - 20:49 , via Wikimedia Commons" data-entity-type="file" data-entity-uuid="c7a7fa8b-b2fe-4d84-a75e-d1ba3a4e2caf" src="[link] width="742" height="249" loading="lazy" /> Ecm85, CC BY-SA 3.0

Therapies 52

Therapies Molecular Biology Immune Response Science 52

Broad Institute

NOVEMBER 6, 2024

Earlier this year, the researchers shared their first translational results, describing the immune cell response underlying colon inflammation in patients undergoing ICI therapy. These are home-run, breakthrough therapies, and quite an amazing success story. How did you go about launching this effort?

Research 124

Research Immune Response Hospitals Therapies 124

FDA Law Blog: Drug Discovery

DECEMBER 7, 2022

Valentine — On November 22, 2022, FDA approved CSL Behring’s BLA for Hemgenix (etranacogene dezaparvovec), an AAV-based gene therapy for the treatment of adults with Hemophilia B who currently use Factor IX prophylaxis therapy, have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes.

Therapies 119

Therapies FDA FDA Approval Treatment 119

Elrig

MAY 18, 2023

The most important drug discovery event of the year? 18-19 October 2023 The most important drug discovery event of the year? It’s with great excitement that we announce the return of ELRIG’s FREE TO ATTEND Drug Discovery 2023 (DD 2023); Europe’s leading event for the drug discovery community! Save the date! Save the date!

Drugs 52

Drugs Science Research Therapies 52

The Pharma Data

JUNE 30, 2021

With a median follow-up of two years, the study met the primary endpoint of event-free survival (EFS; hazard ratio 0.398, p <0.0001). Event-free survival is defined as time from randomization to disease progression, commencement of new lymphoma therapy, or death from any cause. This press release features multimedia.

Therapies 52

Therapies Treatment Virus Vaccine 52

Alta Sciences

JANUARY 11, 2024

It is estimated that there are over 6,000 monogenic diseases, affecting over 350 million people worldwide; for these diseases, cell and gene therapy may provide hope for a cure. However, there are significant challenges associated with the successful development of these complex, leading-edge therapies. what is the altascientist?

Therapies 52

Therapies Immune Response Disease Virus 52

Advarra

MARCH 20, 2023

The Food and Drug Administration (FDA) recently released new guidance regarding cellular and gene therapy products, one of which may significantly impact early-phase clinical trials of such products. This article explores the implications of this guidance, including new approaches for studies focused on cellular or gene therapies.

Therapies 52

Therapies FDA Trials Clinical Trials 52

Chemical Biology and Drug Design

NOVEMBER 4, 2024

Some researchers hypothesized that the primary event associated with the cholinergic neurotransmitter (acetylcholine) is memory loss and cognitive impairment. Due to the disease's complicated pathogenesis, long-term therapy with a single target candidate is futile. As a result, multitargeted and multifunctional therapies have emerged.

Disease 100

Disease Therapies Research 100

Alta Sciences

JULY 18, 2023

Webinar—Nonclinical Safety Assessment for Gene Therapy Products—Key Considerations lperez Tue, 07/18/2023 - 18:35 Image Website_Webinar_AAV-SoMe_v2.jpg jpg Tags Preclinical Research URL [link] Event End Date Thu, 10/19/2023 - 12:00 Event Start Date Thu, 10/19/2023 - 12:00 Weight 1

Production 40

Production Therapies Research 40

Alta Sciences

DECEMBER 29, 2023

Webinar—Nonclinical AAV Gene Therapy Development–Key Considerations on Study Design, Laboratory Endpoints, and Regulatory Guidance lperez Fri, 12/29/2023 - 18:03 Image Website_Webinar_BioA Gene Therapy.jpg Tags Preclinical Research URL [link] Event End Date Thu, 02/29/2024 - 12:00 Event Start Date Thu, 02/29/2024 - 12:00 Weight 1

Laboratories 40

Laboratories Therapies Research 40

ASPET

AUGUST 2, 2024

Based on previous studies, we hypothesized that vascular senescence increases the risk of bleeding during warfarin therapy. The vascular senescence group tended to experience more bleeding or thromboembolic/ischemic events during one year of follow-up, while there was no statistical difference.

Therapies 100

Therapies Hospitals International 100

The Pharma Data

JUNE 1, 2022

The United States Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to efanesoctocog alfa (BIVV001) for the treatment of people with hemophilia A, a rare and life-threatening bleeding disorder, based on data from the pivotal XTEND-1 P hase 3 stud y.

Therapies 52

Therapies FDA Science Treatment 52

Precision for Medicine

OCTOBER 17, 2023

Precision for Medicine is proud to be attending the 3rd Gene and Cell Therapies: CMC, CGT & Vector Manufacturing Summit in Vienna, Austria. The post 3rd Gene and Cell Therapies: CMC, CGT & Vector Manufacturing Summit(June 20-21) appeared first on Precision For Medicine. Schedule a meeting here.

Therapies 52

Therapies 52

The Pharma Data

JANUARY 19, 2021

Estrogen Therapy Need Not Stop for Gender-Affirming Surgery. 19, 2021 — For transgender and gender nonbinary (TGNB) patients undergoing primary vaginoplasty, perioperative venous thromboembolism (VTE) occurs rarely, regardless of whether hormone therapy is suspended prior to surgery, according to a study published online Jan.

Therapies 52

Therapies International Research 52

The Pharma Data

OCTOBER 18, 2020

In late August, Pfizer announced it was investing an additional $500 million into its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina. Ricci told BioSpace the company has been “investing heavily in gene therapy and in the Raleigh-Durham Research Triangle Park area.” Rendering of Durham location.

Therapies 52

Therapies Science Engineering Research 52

The Pharma Data

MAY 27, 2022

Novartis today announced the US Food and Drug Administration (FDA) has granted accelerated approval for Kymriah ® (tisagenlecleucel) for the treatment of adult patients with relapsed or refractory (r/r) follicular lymphoma (FL) after two or more lines of systemic therapy.

FDA Approval 52

FDA Approval Therapies FDA Treatment 52

The Pharma Data

AUGUST 4, 2020

Novartis is celebrating the success of its one-time CAR T therapy Kymriah (tisagenlecleucel) in patients with relapsed or refractory (r/r) follicular lymphoma (FL), revealing that the therapy met its primary its primary endpoint of complete response rate (CRR) in Phase 2 trials, according to an independent review committee.

Therapies 52

Therapies Treatment Regulations FDA 52

DrugBank

OCTOBER 17, 2024

By harnessing the vast amounts of data generated throughout the development pipeline, pharmaceutical companies can accelerate the discovery of novel therapies, optimize clinical trial design, enhance drug safety monitoring, and deliver personalized medicine, ultimately improving patient outcomes and transforming the future of healthcare.

Drug Development 71

Drug Development Metabolic Stability Clinical Trials Drugs 71

The Pharma Data

JANUARY 4, 2021

Investors can pre-register for the event here. Eduardo Schiffrin, Medical Director, will participate in a panel discussion at the LifeSci Partners 10 th Annual Healthcare Corporate Access Event on Friday, January 8 from 11am Eastern Standard Time. Investors can pre-register for the event here. LAUSANNE, Switzerland, Jan.

Disease 40

Disease Therapies Treatment Production 40

The Pharma Data

MARCH 24, 2021

of women who continued on relugolix combination therapy remained responders (menstrual blood loss < 80 mL) through Week 76 compared with 15.1% of women who continued relugolix combination therapy remained responders through Week 104. of women who discontinued treatment at Week 52 (p < 0.0001). weeks after discontinuation.

Therapies 52

Therapies Treatment Science FDA Approval 52

The Pharma Data

SEPTEMBER 11, 2021

Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for empagliflozin as an investigational treatment for adults with heart failure with preserved ejection fraction (HFpEF), Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced. 2,3 A leading cause of hospitalization in the U.S. o Completion: 2020.

Therapies 52

Therapies Hospitals Clinical Trials Trials 52

Codon

JULY 27, 2023

But what happens if you restore these cone cells, using gene therapy? approved a gene therapy for hemophilia A for the first time. It’s called Roctavian and it’s only available for people who don’t have antibodies against AAV5, which is the viral vector used to deliver the gene therapy. From Moazami et al.

Therapies 52

Therapies RNA DNA Engineering 52

Codon

JULY 27, 2023

But what happens if you restore these cone cells, using gene therapy? approved a gene therapy for hemophilia A for the first time. It’s called Roctavian and it’s only available for people who don’t have antibodies against AAV5, which is the viral vector used to deliver the gene therapy. From Moazami et al.

Therapies 52

Therapies RNA DNA Engineering 52

Drug Discovery Today

FEBRUARY 4, 2022

• Face-to-face event, taking place in London, UK, 26-27th April, will feature two dedicated tracks: ‘Scientific’, focused on seven core therapy areas and ‘Life Sciences Business’ Programme features keynote from George Freeman MP, with an update on the UK Government Life Sciences VisionRegistration for BioTrinity 2022 now available online

Science 113

Science Government Therapies 113

Science Daily: Pharmacology News

JULY 31, 2023

Simply remembering events can trigger brain rhythms, even more so than when people are experiencing the actual event, says a new study. The findings could lay foundations for cognitive impairment therapy and help improve memory.

Therapies 75

Therapies 75

Drug Target Review

AUGUST 6, 2024

Cardiovascular diseases : Atherosclerosis : ADCs could be engineered to target and deliver drugs to atherosclerotic plaques, potentially stabilising them and preventing cardiovascular events. Liver Fibrosis : Targeted therapies using ADCs could help reduce liver fibrosis and prevent the progression to cirrhosis.

Therapies 117

Therapies Pharmaceutical Companies Disease Treatment 117

The Pharma Data

MARCH 30, 2021

Novartis Oncology continues to reimagine cancer care through development of robust radioligand therapy portfolio. We continue to invest in radioligand therapy as one of the four unique platforms of Novartis Oncology. Broad expression of FAP demonstrated in tumors or in tumor stroma across many solid tumors 1 ,2 ,3.

Therapies 52

Therapies Licensing Licensing Protein Expression 52

The Pharma Data

AUGUST 18, 2020

Poseida’s Phase 1 trial that used an investigational CAR T therapy for treating prostate cancer has been suspended due to a patient death. The company said that MAS can be caused by CAR T therapies making the immune system overreact, but it can also be caused by infection or autoimmune disease. . Photo by FDA.

Therapies 52

Therapies Trials FDA Treatment 52

The Pharma Data

JUNE 26, 2021

Other data highlighted in the publication and ASCO presentation: Median time to first symptomatic skeletal event or death was 11.5 in the SOC only arm 1 Serious drug-related treatment emergent adverse events occurred in 9.3% months in the 177 Lu-PSMA-617 plus SOC arm versus 6.8 months in the SOC only arm (P<0.001; ?

Therapies 52

Therapies Treatment International FDA 52

ASPET

MARCH 20, 2024

5 in part due to overexpression of microRNA-9-3p/5p impacting post-transcriptional events. Our laboratory previously demonstrated reduced levels of TOP2β/180 (and the paralog TOP2α/170) in an acquired etoposide-resistant K562 clonal cell line, K/VP.5

DNA 100

DNA Laboratories Therapies Regulations 100

The Pharma Data

SEPTEMBER 27, 2021

Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for empagliflozin as an investigational treatment for adults with coronary failure with preserved ejection fraction (HFpEF), Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced. 2,3 a number one explanation for hospitalization within the U.S.

Therapies 52

Therapies Clinical Trials Hospitals Trials 52

Chemical Biology and Drug Design

FEBRUARY 13, 2024

Some researchers proposed that the symptoms involved in AD (loss of memory, cognitive impairment, and amnesia) are the main event linked to the cholinergic neurotransmitter (acetylcholine). Of the multiple hypotheses for AD, the cholinergic and amyloid-β (Aβ) hypothesis are the main targeting hypothesis for AD.

Disease 100

Disease Treatment Therapies Research 100

Drug Target Review

SEPTEMBER 25, 2024

Most targeted cancer therapies used today operate by inhibiting targets along well-known oncogenic signalling cascades. The reactivation of oncogenic signalling upstream or downstream of the driving oncogene is a well-studied source of resistance to targeted cancer therapies.

Small Molecule 105

Small Molecule Therapies Regulations Treatment 105